Page 165 - Haematologica - Vol. 105 n. 6 - June 2020

IGHV and outcome in CLL: a population-based study
haematologica | 2020; 105(6)
1623
A
B
Figure 1. Consort diagrams displaying inclusion and exclusion criteria. All patients in the Chronic Lymphocytic Leukemia registry with complete data were included in the main analyses. (A) Treatment-specific analyses were conducted for the four main treatment groups as illustrated (B) Patients eligible for clinical record review, with detailed data on first- and second-line treat- ment, were included in the analyses of treatment-free survival from the time of treatment. CLL: chronic lymphocytic leukemia; IGHV: immunoglobulin heavy-chain variable region gene; U-CLL: unmutated IGHV CLL; M-CLL: mutated IGHV CLL; CIT: chemoimmunotherapy; FC: fludarabine and cyclophosphamide; B: bendamustine; R: rituximab; Chlor: Chlorambucil; FCR: fludarabine, cyclophosphamide and rituximab; BR: bendamustine and rituximab; CD20-Chlor: chlorambucil and anti-CD20 antibodies.